Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

3rd Annual Stability Testing Conference

Next-Gen Sequencing Trends 2009

Competitor Analysis: c-MET/HGF Inhibitors

The Japanese Pharmaceutical Market 2008-2023

New Products

Japanese Pharmaceutical Market 2009-2024

3rd Annual Lyophilisation Conference

The Global Bioinformatics Market: Market size, forecasts and company profiles

Pharmaceutical Mergers and Acquisitions (PH133)

Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

The Global Analgesics Market 2009-2024

Competitor Analysis: Coagulation Factors

Competitor Analysis: PDGF-R Agonists and Antagonists

World Market for Addiction Disorders, 2009-2016

BioPortfolio | Donald Macarthur | Access to Hospital Pharmaceutical Markets in the United Kingdom

Access to Hospital Pharmaceutical Markets in the United Kingdom

Public hospitals represent a very important market segment for most biopharmaceutical companies in Europe. They are the often the only market for the increasing numbers of speciality products emerging from R&D, with many primary care products also unable to get established for maintenance therapy in the community without hospital recommendation first. Though the processes for achieving hospital usage are very different to the reimbursed GP/community pharmacy sector, they remain poorly documented and often little understood.

This Justpharmareports' publication aims to clarify the situation for the UK, a particularly challenging country with four different public healthcare systems, numerous stakeholders, regular reforms, and rigorous health technology assessment. Medicines prescribed in English hospitals alone in 2006 were valued at £2.7 billion (€3.4 billion/$5.4 billion). This represented 24% of the English NHS drugs bill (but hospital prescribing in London accounted for 40% of all prescribing costs). Even more significantly, the hospital drug bill has been rising at more than twice the rate of GP prescribing costs.

'Access to Hospital Pharmaceutical Markets in the UK' provides:

· Comprehensive and clear information on how medicines for hospital use get selected, purchased, distributed, prescribed, dispensed and paid for.

· Separate sections on England, Scotland, Wales and Northern Ireland.

· Full coverage of the NHS plus two of the largest private providers.

· Explanation of tendering, contracting, contract adjudication and other aspects of procurement.

· Clarification of the DRGtype funding system, Payment by Results.

· Special focus on oncology.

· What discounts hospitals expect and why value added tax is a concern.

· Features on risk sharing schemes and on the boom in homecare services.

· NICE, the PPRS and much, much more...

Author: Donald Macarthur

First published: August 2008

Length: 81 pages A4

Format: PDF
Table of Contents
Price: $1,350.00 / €903.15

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions